Global Active Implantable Medical Devices Market Size study & Forecast, by Product (Implantable Cardioverter Defibrillators, Ventricular Assist Devices, Implantable Heart Monitors/Insertable Loop Recorders, Neurostimulators, Implantable Hearing Devices) a

Global Active Implantable Medical Devices Market Size study & Forecast, by Product (Implantable Cardioverter Defibrillators, Ventricular Assist Devices, Implantable Heart Monitors/Insertable Loop Recorders, Neurostimulators, Implantable Hearing Devices) and Regional Analysis, 2022-2029

Global Active Implantable Medical Devices Market is valued at approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Active implantable medical devices are those that are designed to be fully or partially implanted into a patient's body. These tools are designed to be used in the human body for either therapeutic or diagnostic purposes. The devices can enter the body surgically or through a natural orifice. One of the key factors boosting the market for active implanted medical devices is the rising prevalence of cardiovascular disorders in the world. The market is growing quickly due to investments in funding the development of technologically improved devices and favorable reimbursement factors for ENT treatments in developed nations. The market is also impacted by the increase in neurological disorders and the expansion of applications for neurostimulators. Additionally, the rise in the prevalence of the geriatric population, surge in healthcare spending, improvements in the healthcare infrastructure, and high disposable income are anticipated to support the market growth.

The rising prevalence of cardiovascular diseases is anticipated to create a lucrative demand for the market. The purpose of active implantable medical devices, such as pacemakers, biventricular pacemakers, implantable cardioverter defibrillators (ICD), and cardiac loop recorders, is to help control or monitor irregular heartbeats in persons with certain heart rhythm abnormalities and heart failure. Thus, the rising cardiovascular diseases are anticipated to support the market growth. For instance, according to the research study published in December 2021, by Elsevier, for older people aged 45 and above, the overall self-reported prevalence of diagnosed cardiovascular diseases (CVDs) was 29.4%. The prevalence rate increased with age, from 22% in the 45–54 age group to 38% in the 70+ age group, showing that the senior population is at high risk of having CVDs. Also, according to the World Health Organization (WHO) report 2021, there were approximately 17.9 million deaths due to cardiovascular diseases in 2019, which shows nearly 32% of all deaths globally. In addition, as per the National Library of Medicine, India is recorded with the highest burden of cardiovascular disease (CVD) globally. The total number of deaths from CVD in India is estimated to grow from 2.26 million (1990) to 4.77 million (2020). Additionally, technological advancement in active implantable medical devices is anticipated to provide lucrative opportunities for the market during forecast period. However, the dearth of skilled professionals stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Active Implantable Medical Devices Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players, rising geriatric population, growing prevalence of cardiovascular and neurological diseases, and high accessibility to advanced technologies in the region. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period, owing to factors such as rising geriatric and target populations, increasing incidence of chronic diseases, growing healthcare spending, healthcare reforms for infrastructural development, and rising demand for advanced technologies to develop advanced products.

Major market players included in this report are:
Medtronic plc (Ireland)
Abbott Laboratories (U.S.)
Boston Scientific Corporation (U.S.)
BIOTRONIK SE & Co. KG (Germany)
LivaNova PLC (U.K.)
Cochlear Limited (Australia)
MED-EL (Austria)
Sonova Holding AG (Switzerland)
William Demant Holding A/S (Denmark)
Nurotron Biotechnology Co., Ltd. (China)

Recent Developments in the Market:
In February 2022, Abbott announced the launch of implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i pivotal medical trial. The first implant of Abbott's innovative Aveir dual-chamber leadless pacemaker to take place globally within the pivotal trial marks a significant technology milestone for leadless pacing technology.

Global Active Implantable Medical Devices Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Implantable Cardioverter Defibrillators
Ventricular Assist Devices
Implantable Heart Monitors/Insertable Loop Recorders
Neurostimulators
Implantable Hearing Devices

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Medtronic plc (Ireland)
Abbott Laboratories (U.S.)
Boston Scientific Corporation (U.S.)
BIOTRONIK SE & Co. KG (Germany)
LivaNova PLC (U.K.)
Cochlear Limited (Australia)
MED-EL (Austria)
Sonova Holding AG (Switzerland)
William Demant Holding A/S (Denmark)
Nurotron Biotechnology Co., Ltd. (China)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.